Clinical Trial

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

Study acronym: ROUTE-C3G
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to characterize the patient profiles and the clinical experience of iptacopan treatment in adult patients with C3G treated through an early access program (EAP) in Spain.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-09-30 -> 2026-12-15 2026-07-01
minor Completion pushed: 2026-09-30 -> 2026-12-15 2026-07-01
Trial Details
NCT Number NCT07598448
Lead Sponsor Novartis Pharmaceuticals
Conditions Complement 3 Glomerulopathy
Enrollment 35 participants
Start Date 2026-08-23
Primary Completion 2026-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-13